Unlock the IQIRVO▼ (elafibranor) effect

For healthcare professionals caring for people prescribed IQIRVO.

Abbreviations
PPAR, peroxisome proliferator-activated receptor; UDCA, ursodeoxycholic acid.

Footnote
*IQIRVO + UDCA met the primary endpoint of cholestasis response, defined as by ALP <1.67 x ULN, and ALP decrease ≥15% and TB ≤ULN. Reduction in ALP and bilirubin is predictive of long-term outcomes.^1–5

References

1. IQIRVO® (elafibranor) Summary of product characteristics (SmPC). 2024
2. Lammers WJ et al. Gastroenterology. 2014;147(6):1338–1349.
3. Corpechot C et al. Clin Res Hepatol Gastroenterol. 2022;46(1):101770.
4. de Veer RC et al. Aliment Pharmacol Ther. 2022;56(9):1408–1418.
5. Murillo Perez CF et al. Am J Gastroenterol. 2020;115(7):1066–1074.